Fonte: Surgery for obesity and related diseases. Unidade: FM
Assuntos: HIPERTENSÃO, FATORES DE RISCO, DERIVAÇÃO GÁSTRICA, DOENÇAS METABÓLICAS, CARDIOPATIAS, ENSAIO CLÍNICO, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SCHIAVON, Carlos Aurelio et al. Does the RYGB common limb length influence hypertension remission and cardiometabolic risk factors? Data from the GATEWAY trial: data from the GATEWAY trial. Surgery for obesity and related diseases, v. 15, n. 2, p. 211-217, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.soard.2018.11.022. Acesso em: 01 out. 2024.APA
Schiavon, C. A., Santos, R. N., Santucci, E. V., Noujaim, P. M., Cavalcanti, A. B., & Drager, L. F. (2019). Does the RYGB common limb length influence hypertension remission and cardiometabolic risk factors? Data from the GATEWAY trial: data from the GATEWAY trial. Surgery for obesity and related diseases, 15( 2), 211-217. doi:10.1016/j.soard.2018.11.022NLM
Schiavon CA, Santos RN, Santucci EV, Noujaim PM, Cavalcanti AB, Drager LF. Does the RYGB common limb length influence hypertension remission and cardiometabolic risk factors? Data from the GATEWAY trial: data from the GATEWAY trial [Internet]. Surgery for obesity and related diseases. 2019 ; 15( 2): 211-217.[citado 2024 out. 01 ] Available from: https://doi.org/10.1016/j.soard.2018.11.022Vancouver
Schiavon CA, Santos RN, Santucci EV, Noujaim PM, Cavalcanti AB, Drager LF. Does the RYGB common limb length influence hypertension remission and cardiometabolic risk factors? Data from the GATEWAY trial: data from the GATEWAY trial [Internet]. Surgery for obesity and related diseases. 2019 ; 15( 2): 211-217.[citado 2024 out. 01 ] Available from: https://doi.org/10.1016/j.soard.2018.11.022
